Osteomalacia is defined as a defect in mineralization of the bone matrix. We describe the case of a patient with chronic hepatitis B infection in whom treatment with adefovir induced renal phosphate loss with intense and sustained hypophosphatemia which derived in symptomatic osteomalacia.

Key Messages Octreotide can be used as an adjunctive therapy to increase phosphorus levels in patients with tumor-induced osteomalacia. Malignant phosphaturic mesenchymal tumor (PMT) may benefit from treatment with peptide receptor radionucleotide therapy. Context The success of treatment modalities for malignant PMT is limited. Octreotide has been used to treat hypophosphatemia in patients w...

Background Osteomalacia is a bone disorder characterized by decreased mineralization. Vitamin D deficiency and hypophosphatemia are the most frequent causes. Fibroblast growth factor 23 (FGF23) hormone secreted osteocytes in response to increased calcitriol serum phosphate levels. FGF23 main function levels regulation, decreasing sodium-phosphate cotransporter expression on proximal convoluted ...

In this issue of JBMR, Jan de Beur and colleagues(1) report the primary analysis findings up to closure their prospective, open-label, single-arm, phase 2 study (NCT02304367) evaluate safety efficacy burosumab-twza for treating adults with a debilitating disorder, tumor-induced osteomalacia (TIO). Burosumab is fully human monoclonal antibody against phosphatonin fibroblast growth factor-23 (FGF...